Home › Trial NCT06498648
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- Trial IDNCT06498648
- StatusRecruiting
- PhasePhase 1/2
- Study typeInterventional
- SponsorNational Cancer Institute (NCI)
- Enrollment74
- Start date2026-03-18
- ConditionsAdvanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma · Metastatic Leiomyosarcoma · Metastatic Soft Tissue Sarcoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.